IBM to build biometrics system for UK cops and immigration services
The UK's Home Office has handed IBM a £54.7 million contract to work on the biometric matcher platform to support its police and immigration services in identifying suspects against a database of fingerprint and photo data.
Big Blue's deal is to provide the Matcher Service Platform , which includes a"service bus" to provide biometric transaction processing logic, biometric workflow rules, integration of matching engine software and a service interface used by external subsystems”, according toThe American tech biz will also create an infrastructure platform to host and provide the computing capacity for these services.
The contract, which set to run for a five-year term with an option to extend for a further three years, will transition and manage the existing Matcher Platform, built by Fujitsu, as well as creating new search capabilities and the decommissioning of legacy algorithms for a police service biometric data service IDENT1 and the immigration and asylum biometric information system . to provide the Biometric Matcher Platform and associated Services , in a deal which was set to end in March 2023.
Separate services run IDENT1 and IABS. In 2018, Home Office launched plans to move service management of the IDENT1 and IABS systems to a single supplier. IDENT1 had beenIn Jan 2018, Home Office over six years, rising to £308 million if the engagement lasts for the full 10 years, according to a tender notice published at the time.
In 2019, the central government department responsible for policing and securing UK borders awarded the six-year deal to global systems integrator
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
‘They were here before the dinosaurs': Horseshoe crabs get new protections thanks to valuable blue bloodA primordial sea animal that lives on the tidal mudflats of the East Coast and serves as a linchpin for the production of vital medicines stands to benefit from new protective standards.
Read more »